NCT05940311
- Conditions
- Liquid Biopsy, Melanoma, Melanoma (Skin), +13 more
- Locations
-
- "Regina Elena" National Cancer Institute Rome, Italy
Clinical trial condition
Melanoma
Explore clinical trials studying Melanoma. Study availability and eligibility vary by location and protocol.
2,208 public trials
376 recruiting studies
Melanoma trial results
NCT04787042
- Conditions
- Adenocarcinoma, Breast Diseases, Breast Neoplasms, +43 more
- Locations
-
- HonorHealth Research Institute Scottsdale, Arizona, United States
- Sarah Cannon Research Institute at HealthONE Denver, Colorado, United States
- Yale Cancer Center New Haven, Connecticut, United States
- Moffitt Cancer Center Tampa, Florida, United States
NCT06240143
- Conditions
- Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
- Locations
-
- Amsterdam University Medical Center Amsterdam, Netherlands
- Antoni van Leeuwenhoek Hospital Amsterdam, Netherlands
- University Medical Center Groningen Groningen, Netherlands
- Leiden University Medical Center Leiden, Netherlands
NCT06680323
- Conditions
- Congenital Nevi, Disease Attributes, Disease Susceptibility, +16 more
- Locations
-
- Leibniz Research Institute for Environmental Medicine Düsseldorf, Germany
- University of Florence Florence, Italy
- Istituto Nazionale del Tumori Milan, Italy
- Medical University of Gdánsk Gdansk, Poland
Recruiting
DermaSensor Postmarket Surveillance Study
NCT06666790
- Conditions
- Melanoma, Melanoma, Skin, Neoplasms, +10 more
- Locations
-
- Velocity New Smyrna Beach, Florida, United States
- West Clinical Research Morehead City, North Carolina, United States
NCT06284590
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, +11 more
- Locations
-
- Memorial Sloan Kettering Cancer Center New York, United States
Recruiting
NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
NCT06651151
- Conditions
- Melanoma, Melanoma Stage IIIB-IV, Neoplasms, +10 more
- Locations
-
- Oslo University Hospital Oslo, Norway
Recruiting
Biomarkers in Immunotherapy of Melanoma
NCT05878977
- Conditions
- Exosomal mRNA Expression of PD-L1 and IFNγ, Gastrointestinal Microbiome (Bacterial and Viral), Immune Checkpoints Inhibitors, +13 more
- Locations
-
- Institute of Oncology Ljubljana Ljubljana, Slovenia
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Kidney Diseases, +25 more
- Locations
-
- Groupement hospitalier Est - Multidisciplinary oncological platform Bron, France
- Hôpital Louis Pradel - Department of Pneumology Bron, France
- University hospital of Grenoble Alpes - Department of dermatology Grenoble, France
- University hospital of Grenoble Alpes - Department of Medical Oncology Grenoble, France
Recruiting
Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
NCT05878964
- Conditions
- Bladder Cancer, Breast Cancer, Breast Diseases, +41 more
- Locations
-
- Roberto Iacovelli Roma, Italy